Nureca Limited reported strong financial performance for FY26 with consolidated revenue growing 34% to ₹1,469.93 million and PAT surging 146% to ₹20.82 million. EBITDA increased 69% to ₹82.78 million with margin expansion from 4.46% to 5.63%. GMV grew 17.5% to ₹2,029.86 million.
The company completed a significant share buyback of 458,255 equity shares (4.58% of capital) at ₹330 per share, utilizing ₹151.22 million. This resulted in share capital reduction from 10,000,175 to 9,541,920 shares and transfer of ₹4.58 million to Capital Redemption Reserve.
Major management changes include the resignation of CFO Naresh Gupta (effective June 26, 2026) and Whole-time Director & CEO Aryan Goyal (effective July 1, 2026). New appointments include Chander Kant as CFO (effective June 27, 2026) and Smita Goyal as Whole-time Director (effective June 1, 2026). Saurabh Goyal continues as Chairman & Managing Director with reappointment proposed for 3 years.
Subsidiary updates include dissolution of Nureca Healthcare Private Limited and ongoing merger process of Nureca Technologies Private Limited with the parent company, pending NCLT approval. The company is establishing a new manufacturing facility in Punjab as part of its "Make in India" strategy and expanding the Dr Trust 360 connected health platform with AI-powered features.
Balance sheet shows cash and equivalents of ₹14.61 million, investments of ₹10.12 million, and bank deposits of ₹1,038.88 million. Net worth decreased 6.96% to ₹1,807.60 million due to the buyback. The board did not recommend any dividend for FY26.
Legal proceedings include GST matters totaling ₹47.13 million and income tax dispute of ₹0.21 million. The company reported contingent liabilities and MSME dues of ₹7.43 million principal plus interest. Corporate governance metrics show 6 board meetings and various committee meetings held during the year.